Fabiani c, et al. - In patients with non-infectious intermediate uveitis, posterior uveitis, and panuveitis, researchers compared the effectiveness of dalimumab (ADA) and infliximab (IFX). Among patients treated with ADA, the frequency of uveitic macular edema (UME) was significantly higher vs those treated with IFX at the 12-month assessment and at the last follow-up visit. In ADA group, central macular thickness was significantly higher vs the IFX group at the last follow-up assessment. A similar efficacy in controlling uveitis relapses was demonstrated by ADA and IFX, but a more pronounced corticosteroid-sparing effect and a significantly higher capacity in resolving UME were demonstrated by IFX vs ADA.